Trials / Unknown
UnknownNCT04341207
Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients
COVID 19 - Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease Upon Hydroxychloroquine and Azithromycin Therapy in French Cancer Patients
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1,000 (estimated)
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine the prevalence and the 3-months incidence of SARS-CoV-2 in cancer patients (Part A). To evaluate the Covid-19 disease-specific mortality rate in cancer patients treated by hydroxychloroquine and azithromycin (Part B).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Hydroxychloroquine | Hydroxychloroquine 200 mg 3 times a day for 10 days |
| DRUG | Azithromycin | Azithromycin 500 mg on day 1 followed by 250 mg/day for 4 days |
Timeline
- Start date
- 2020-04-03
- Primary completion
- 2022-04-01
- Completion
- 2022-04-01
- First posted
- 2020-04-10
- Last updated
- 2020-04-10
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT04341207. Inclusion in this directory is not an endorsement.